Skip to Main Content U.S. Department of Energy
Biological Sciences

Human Disease Research


PNNL hosts a National Center for Research Resources (NCRR) Proteomics Research Resource for Integrative Biology (Contact: Dr. David Camp). The long-term goal of this Center is to develop and make advanced proteomic technologies more accessible to and useful for the biomedical research community. Collaborative projects drive the technology development, including data analysis and informatics to further extend state of the art proteomics for resolving medically important biological questions.

Collaborative projects span areas of research emphasis that include neuroproteomics, pathogenesis, post translational modifications, oncology, lipid raft cell signaling, host-pathogen interactions, infection-induced secretome, mechanism of cell migration, quantitative measurements of time course investigations, and low dose radiation exposure, cell-signaling, and DNA repair mechanisms. These programs include

  • HIV Proteomic Center for Host-Viral Response Characterization, National Institute on Drug Abuse. We are applying new proteomics technologies to broadly investigate changes in protein abundances resulting from the pathologic events associated with concomitant lentiviral infection and substance abuse, as well as from pharmacologic interventions designed to treat these pathologies.
  • Proteomics Studies of Type II Diabetes using a Mouse Knockout Model, National Institute of Diabetes and Digestive and Kidney Diseases. We are applying global quantitative proteomic technologies to study unique insulin-resistant knockout mouse models to identify novel islet proteins and circulating factors that regulate -cell replication and survival. Functional studies are looking at key novel protein players to gain better understanding of the mechanisms and factors that regulate islet growth.
  • Next Generation Clinical Proteomics to Target Human Health Challenges, Washington State Life Sciences Discovery Fund. We are implementing a "next generation" proteomics platform for discovery of candidate protein biomarkers present in patients either diagnosed with or at risk of liver fibrosis and disease. The program involves a diverse group of investigators within the Washington state (University of Washington, PNNL, and Fred Hutchinson Cancer Research Center) who possess significant expertise in the fields of basic science, virology, biostatistics, clinical medicine, and advanced proteomics technologies.

Our biomarker work also includes research on the following health issues:

  • Inflammation and the host response to injury (NIGMS Glue Grant)
  • Liver fibrosis and disease
  • Women's cancer programs (Entertainment Industry Foundation

Biological Sciences

Science at PNNL

Research Highlights

View All BSD Highlights